AtriCure Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Kroger (KR) To Cut Corporate Workforce By About 3,000 Over 3 Years - Bloomberg
- Sysco calls on Teamsters to end LA strike after economic deal reached
AtriCure Inc. (ATRC) PT Lowered to $53 at BTIG
July 31, 2024 4:58 AM EDTBTIG analyst Marie Thibault lowered the price target on AtriCure Inc. (NASDAQ: ATRC) to $53.00 (from $58.00) while maintaining a Buy rating.
The analyst comments "AtriCure reported Q2 revenue of $116.3M (+15.2% y/y rep, +15.4% y/y cc), in line with consensus of $116.2M. U.S. Q2 revenue was $95.5M (+12.5% y/y), lower than consensus of $97.1M, while International revenue of $20.7M (+29.4% y/y rep, +30.4% y/y cc) beat consensus of $19.0M. The U.S. Appendage Management segment reported $37.9M (+11.8% y/y) in Q2 sales, missing consensus of $38.3M by $400K. However, growth in... More



